3.2 Data mining
In current study, we selected reports containing products
“lenvatinib”, “sorafenib”,
“cabozantinib” and “regorafenib” as “primary suspect” for further
study. Arbitrary drug names may be reported in the FAERS, therefore, the
MICROMEDEX® (Index Nominum) was utilized as a dictionary for TKIs(Table
1). The suspected adverse events(AEs) were coded according to the
Medical Dictionary for Regulatory Activities (MedDRA®). We grouped
cardiac AEs in the MedDRA classification (version 25.1) that are related
to the same medical condition.